{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T13:24:07Z","timestamp":1781961847565,"version":"3.54.5"},"reference-count":68,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T00:00:00Z","timestamp":1416787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"crossref","award":["AIRC 2013 IG-14249"],"award-info":[{"award-number":["AIRC 2013 IG-14249"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:p>The initial treatment for chronic myeloid leukemia in chronic phase (CP\u2010CML) represents a complex process, which includes a prompt and precise diagnosis, the choice among three available tyrosine kinase inhibitors (TKIs), and the initial management of care for these patients, which will protract over a very long period of time. This manuscript summarizes different data on activity, side effects, and supportive measures available for each TKI, the need for particular care in the logistical organization of CML management, the scenario which will be opened by the future availability of generic imatinib. The opinion of the authors is that imatinib remains the first\u2010line treatment for CP\u2010CML; this strategy, accompanied by intensive monitoring and possible dose modification\/drug switch after the initial 3\u201312 months of treatment presently assures a normal life expectancy to the population of newly diagnosed patients with CP\u2010CML. Am. J. Hematol. 90:156\u2013161, 2015. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23887","type":"journal-article","created":{"date-parts":[[2014,11,5]],"date-time":"2014-11-05T07:00:49Z","timestamp":1415170849000},"page":"156-161","source":"Crossref","is-referenced-by-count":18,"title":["How <scp>I<\/scp> treat newly diagnosed chronic myeloid leukemia in 2015"],"prefix":"10.1002","volume":"90","author":[{"given":"Carlo","family":"Gambacorti\u2010Passerini","sequence":"first","affiliation":[{"name":"Department of Health Sciences University of Milano\u2010Bicocca, Section of Hematology, San Gerardo Hospital Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Piazza","sequence":"additional","affiliation":[{"name":"Department of Health Sciences University of Milano\u2010Bicocca, Section of Hematology, San Gerardo Hospital Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,11,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.1997.0155"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3691"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr060"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23804"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr073"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq262"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7146"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.096776"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_10_21_1","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen MH","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-103523"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21942"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324228"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004095"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.225"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23501"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347575"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.06.020"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1446"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0107-13b"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.09.021"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-057521"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35721"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_10_41_1","article-title":"Patient\u2010driven discontinuation of tyrosine kinase inhibitors: Single institution experience","author":"Benjamini O","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.01.033"},{"key":"e_1_2_10_43_1","first-page":"283","volume-title":"Age and Digital\u2010PCR Analysis Predict Relapses of CML Patients Following Programmed Imatinib Interruption in Q\u2010RT\u2010PCR Negatice Chronic Myeloid Leukemia Patients","author":"Mori S","year":"2014"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12423"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_2_10_47_1","article-title":"Frontline Nilotinib Results In Superior Rates of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML\u2010CP): ENESTchina 12\u2010Month Primary Analysis Abstract 1497","author":"Huang X","year":"2013","journal-title":"ASH"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9230"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410688"},{"key":"e_1_2_10_50_1","first-page":"1673","article-title":"Second\u2010generation BCR\u2010ABL kinase inhibitors in CML","volume":"363","author":"Simonsson B","year":"2010","journal-title":"N Engl J Med"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc053425"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369041"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"e_1_2_10_54_1","volume-title":"Abstract 257","author":"Hadzijusufovic E","year":"2013"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22037"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr292"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11680"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544015"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.69"},{"issue":"1","key":"e_1_2_10_60_1","article-title":"Long\u2010Term Assessment of Cardiac Toxicity in Patients with Ph+ Leukemias Treated with Bosutinib","volume":"99","author":"Gambacorti\u2010Passerini C","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"e_1_2_10_61_1","article-title":"Long\u2010term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib","volume":"32","author":"Cortes JE","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800912800190965"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-566323"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11729"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"e_1_2_10_66_1","first-page":"C1","article-title":"Our ailing medical system","author":"Jauhar S","year":"2014","journal-title":"Wall Street J"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23887","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T09:13:51Z","timestamp":1696583631000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,24]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1002\/ajh.23887"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23887","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,24]]}}}